Telix pharmaceutical/$TLX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Telix pharmaceutical
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
Ticker
$TLX
Sector
Primary listing
Employees
423
Headquarters
North Melbourne, Australia
Website
TLX Metrics
BasicAdvanced
$3.7B
256.10
$0.04
2.28
-
Price and volume
Market cap
$3.7B
Beta
2.28
52-week high
$30.36
52-week low
$8.93
Average daily volume
176K
Financial strength
Current ratio
1.333
Quick ratio
1.108
Long term debt to equity
94.134
Total debt to equity
99.126
Interest coverage (TTM)
2.64%
Profitability
EBITDA (TTM)
36.406
Gross margin (TTM)
53.94%
Net profit margin (TTM)
1.63%
Operating margin (TTM)
4.23%
Effective tax rate (TTM)
-19.94%
Revenue per employee (TTM)
$1,570,000
Management effectiveness
Return on assets (TTM)
2.08%
Return on equity (TTM)
3.14%
Valuation
Price to earnings (TTM)
256.098
Price to revenue (TTM)
4.181
Price to book
13.59
Price to tangible book (TTM)
-35.36
Price to free cash flow (TTM)
-218.825
Free cash flow yield (TTM)
-0.46%
Free cash flow per share (TTM)
-0.05
Growth
Revenue change (TTM)
55.35%
Earnings per share change (TTM)
-45.24%
3-year revenue growth (CAGR)
227.92%
3-year earnings per share growth (CAGR)
-45.54%
Bulls say / Bears say
The FDA has requested additional data on Telix’s kidney cancer imaging drug Zircaix because of deficiencies in manufacturing and supply chain, postponing its U.S. approval and commercial launch plans (Reuters).
Telix shares dropped as much as 24% in early trading and closed nearly 19% lower on the ASX following the FDA’s request, marking the stock’s steepest single-day decline to date and highlighting serious investor concerns about regulatory obstacles (Reuters).
Telix has a trailing P/E of around 337x and trades at approximately 146x price-to-cash flow, which signals high valuation risk should its commercial execution or drug pipeline fail to meet expectations (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 5 Oct 2025.
TLX News
AllArticlesVideos
Telix Pharmaceuticals Enters Q4 On Strong Footing With Stabilized Pricing Pressures, Upgraded Annual Sales Guidance
Benzinga1 week ago
Telix Gets Second FDA Rejection For Kidney Cancer Drug
Benzinga2 months ago
US FDA seeks more information on Telix Pharma's diagnostic drug for kidney cancer
Reuters2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Telix pharmaceutical stock?
Telix pharmaceutical (TLX) has a market cap of $3.7B as of October 22, 2025.
What is the P/E ratio for Telix pharmaceutical stock?
The price to earnings (P/E) ratio for Telix pharmaceutical (TLX) stock is 256.1 as of October 22, 2025.
Does Telix pharmaceutical stock pay dividends?
No, Telix pharmaceutical (TLX) stock does not pay dividends to its shareholders as of October 22, 2025.
When is the next Telix pharmaceutical dividend payment date?
Telix pharmaceutical (TLX) stock does not pay dividends to its shareholders.
What is the beta indicator for Telix pharmaceutical?
Telix pharmaceutical (TLX) has a beta rating of 2.28. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.